Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01418053
Other study ID # 11-4627 CarO
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2011
Est. completion date September 2013

Study information

Verified date May 2018
Source Universität Duisburg-Essen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a daily use of a Kneipp hot cataplasm with caraway oil is effective in the treatment of abdominal pain and complaints caused by Irritable bowel syndrome.


Description:

see above.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Irritable Bowel Syndrome according to Rom-III

- Subtype Diarrhea or Alternating

- discomfort or pain > 1 times a week

- discomfort or pain > 4 on a Visual Analog Scale

Exclusion Criteria:

- Inflammatory bowel diseases (test results necessary)

- Lactose, Fructose Malabsorption (test results necessary)

- Celiac Disease

- Pregnancy or Breastfeeding

- Colectomy or Hemicolectomy >50cm

- Severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver or renal diseases

- severe depression, psychotic or psychiatric disorders, substance abuse

- cancer within the last 5 years

- allergy to caraway

- acute inflammatory diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
caraway oil
essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
Olive oil
1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned

Locations

Country Name City State
Germany Klinik für Naturheilkunde und Integrative Medizin Essen

Sponsors (1)

Lead Sponsor Collaborator
Universität Duisburg-Essen

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Lauche R, Janzen A, Lüdtke R, Cramer H, Dobos G, Langhorst J. Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome--A Randomized Controlled Cross-Over Trial. Digestion. 2015;92(1):22-31. doi: 10.1159/000398790. Epub 2015 Jun 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Irritable Bowel Syndrome - Symptom Severity Score IBS-SSS (Francis 1997) at T2 (Day 21)
Secondary Frequency of abdominal discomfort/Pain Diary, daily rating of pain last week of treatment (days 14-21)
Secondary Intensity of abdominal discomfort/Pain Daily rating of pain intensity on a 100mm Visual analogue scale, pain diary last week of treatment (days 14-21)
Secondary Quality of life measured with the EQ-5D T2 (Day 21)
Secondary Quality of life - ibs specific measured with the IBS-QOL (Patrick, 1998) T2 (day 21)
Secondary Depression and Anxiety HADS questionnaire (Hermann, 1995) T2 (day 21)
Secondary Global improvement Question on global improvement: How have your symptomes changed compared to the last week: from much worse to much better on a 7-point scale At day 7, 14 and 21
Secondary h-BD2 h-BD2 laboratory findings T2 (day 21)
Secondary Adequate Relief Score Adequate Relief Score (Mangel, 1998) at day 7, 14, 21
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A